My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October

The article highlights Ares Capital, Enterprise Products Partners, and Pfizer as high-yield dividend stocks positioned to withstand inflation, rate hikes, and geopolitical uncertainty, offering forward yields of more than 10%, about 6.3%, and more than 6%, respectively. Ares Capital reported 17% year-over-year AUM growth in Q2 2026, 20% growth in fee-related earnings, and over 30% growth in realized income, with 94% of new commitments at floating rates. Enterprise is benefiting from U.S. natural-gas-liquids export demand and AI-related data-center power needs, while Pfizer expects high-single-digit revenue CAGR after 2028 despite major patent expirations and has reiterated its commitment to maintaining its dividend.

Analysis

ARCC is not a clean long-duration “higher rates” trade: floating-rate asset income is largely offset once borrowers hit stress thresholds, while its own funding costs and non-accruals rise with a restrictive Fed. The more investable 1-3 month catalyst is resilient base rates plus stable credit spreads, which supports spillover income and NAV; the 6-18 month risk is that lower-middle-market defaults lag policy tightening by several quarters. A widening in ARCC non-accruals above roughly 3% of fair value, or a meaningful decline in net investment income per share, would matter more than another modest policy-rate move.

EPD offers a better defensive income profile than upstream energy because contract economics and export infrastructure utilization, rather than spot commodity prices, drive cash generation. However, the AI-power narrative is directionally supportive for gas demand but is not automatically accretive to EPD's NGL-heavy system; the key transmission channel is sustained associated-gas production and export fractionation volumes. The non-obvious risk is a prolonged low-gas-price environment curtailing dry-gas drilling or an LNG-export slowdown, which could cap volume growth even if domestic power demand rises.

PFE's yield should be treated as a valuation signal rather than a catalyst. Dividend maintenance can coexist with weak equity returns if pipeline launches and acquired-product growth fail to replace exclusivity losses quickly enough; deleveraging needs may also compete with business-development spending. Consensus likely underestimates the execution hurdle between regulatory approvals and commercially material launches, making PFE a watchlist value opportunity rather than an immediate income trade absent evidence of upward revisions to post-loss-of-exclusivity revenue estimates.

Key Decisions for Investors

• Initiate a modest 3-6 month long ARCC / short BIZD pair if ARCC trades at or below NAV: ARCC's scale, sponsor access and underwriting platform should outperform smaller BDCs if credit remains benign. Exit if ARCC's non-accrual rate exceeds 3% of fair value or net investment income no longer covers the regular dividend.
• Accumulate EPD on broad energy-market weakness for a 12-18 month income position, but size it as infrastructure exposure rather than a gas-price beta. Target mid-single-digit total-return downside versus low-teens upside from distribution growth plus multiple normalization; reassess if NGL export volumes weaken for two consecutive quarters or leverage moves materially above management's historical range.
• Do not chase PFE solely for yield. Set an earnings alert for upward revisions to 2027-2029 revenue guidance, evidence that new launches are offsetting legacy-product erosion, and net-debt reduction; absent these, prefer a neutral stance because multiple compression can overwhelm the dividend carry.
• For a cleaner AI-power/gas-demand expression, compare EPD against WMB and KMI after next quarterly volume disclosures: favor the operator showing demonstrable pipeline throughput or contracted power-generation/LNG demand rather than relying on thematic estimates.